http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1098124-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2de3beee83d9c19278da409b72c777a8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C401-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1977-03-10^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1981-03-24^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_156db00e2d809bd00983d9dfed3f70f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f9f94acf3c14740a39f51167ae7adfd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8eeae1b777201c1ca98d195cb4e84ad1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59b72f1da74dc80480bf5c440b9dc994 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38d1f7eab49ffaadbbad1144b5f4d753 |
| publicationDate | 1981-03-24^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1098124-A |
| titleOfInvention | Process for the preparation of prostaglandin analogues |
| abstract | ABSTRACT The present invention relates to prostaglandin analogues of the general formula:- wherein X represnts cis or trans-vinylene or ethylene, Z represents or , R1 represents a hydrogen atom or a straingh- or branched-chain alkyl group containing from 1 to 12 carbon atoms, R2 represents a hydrogen atom or a methyl group. R3 represents a straight-or branched-chain alkylene group containing from 1 to 7 carbon atoms and R4 represents a cycloalkyl group containing from 5 to 7 carbon atoms, a grouping of the formula:- (wherein R5 and R6, which may be the same or different, each represent a hydrogen atom or halogen atom, a trifluoromethyl group of a straight- or branched-chain alkyl group containing from 1 to 4 carbon atoms), or a grouping of the formula:- (wherein R5 and R6 are as hereinbefore defined), or R3 and R4 together represent a straight- or branched-chain alkyl group containing from 1 to 10 carbon atoms, and (1) the double bond between C3-C4 is trans or cis or trans and cis, when X is cis-vinylene or ethylene, and (2) the double bond between C3-C4 is trans, when X is trans-vinylene, and the double bond between C13-C14 is trans with the exclusion of these prostaglandin analogues wherein X represents cis-vinylene or ethylene, Z represents , R1 and R2 represent hydrogen atoms, R3 and R4 together represent n-pentyl and the double bond between C3-C4 is trans) and cyclodextrin clathrates of such acids and esters, and when R1 represents a hydrogen atom, non-toxic salts thereof, which exhibit characteristic prostaglandin-like activities. |
| priorityDate | 1976-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 176 of 176.